Core Points - The stock price of Weikang Pharmaceutical has decreased by 2.02% on September 17, trading at 23.32 CNY per share with a market capitalization of 3.377 billion CNY [1] - Year-to-date, Weikang Pharmaceutical's stock has increased by 56.16%, with a recent 5-day increase of 8.31% and a 60-day increase of 43.95% [2] - The company has reported a significant decline in revenue and net profit for the first half of 2025, with revenue of 115 million CNY, down 61.42% year-on-year, and a net loss of 64.22 million CNY, down 552.50% year-on-year [2] Financial Performance - As of June 30, the number of shareholders for Weikang Pharmaceutical is 9,892, a decrease of 12.06% from the previous period, while the average circulating shares per person increased by 13.71% to 14,569 shares [2] - The company has distributed a total of 179 million CNY in dividends since its A-share listing, with 55.4 million CNY distributed over the last three years [3] Business Overview - Weikang Pharmaceutical, established on March 31, 2000, and listed on August 24, 2020, is located in Lishui Economic Development Zone, Zhejiang Province [2] - The company's main business involves the research, production, and sales of modern Chinese and Western medicines, with 97.16% of its revenue coming from traditional and Western medicine products [2] - Weikang Pharmaceutical operates within the pharmaceutical and biotechnology sector, specifically in the Chinese medicine sub-sector, and is involved in concepts such as hepatitis treatment, anti-influenza, and pharmaceutical e-commerce [2]
维康药业跌2.02%，成交额6744.97万元，主力资金净流出289.42万元